Orca Bio's T cell therapy may help blood cancer patients avoid transplant issues
Orca Bio on Monday said its T cell therapy, when used in people with certain blood cancers, reduced the risk of treatment complications seen with bone marrow transplants. The company now ...
View ArticleAll selected drugmakers agree to round 2 of price negotiations
The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place from the manufacturers of those drugs. Twelve manufacturers will negotiate the...
View ArticleAstraZeneca reports Phase 3 win for hypoparathyroidism drug eneboparatide
AstraZeneca’s $1.05 billion bet on French biotech Amolyt Pharma seems to be paying off. On Monday, the UK drugmaker reported a late-stage success for the hypoparathyroidism drug that sparked the...
View ArticleWuXi AppTec's US revenue growth continues to dip in post-Biosecure environment
A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the Chinese manufacturer failed to grow its customer base for the first time in five...
View ArticleAstraZeneca inks deal with Alteogen for subcutaneous cancer drugs
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple oncology therapies. The British pharma will license ALT-B4, a compound that...
View ArticleTrump’s HHS defends Biden-era stance on 340B rebate models
The Trump administration defended HHS’ rejection of drugmakers' 340B rebate models “at this time,” but suggested that the agency could be open to further consideration. The comments, made in response...
View ArticleFDA staff return to White Oak campus after Trump administration push
Packed parking, long security lines and traffic greeted returning FDA workers on Monday, who were called back to the agency's main White Oak campus as part of the Trump administration's effort to force...
View ArticleSofinnova raises €165M for new early-stage biotech fund
European life sciences investor Sofinnova Partners disclosed a €165 million acceleration fund on Tuesday to back early-stage science in Italy, France, the United Kingdom and Denmark. The fund,...
View ArticleCRISPR startup Arbor Biotechnologies raises $73.9M as it nears first trial
Arbor Biotechnologies, a startup founded by CRISPR pioneer Feng Zhang nine years ago, has closed a $73.9 million Series C financing to bring its first therapy into clinical trials — a treatment that...
View ArticleNovartis revamps commercial strategy as Entresto patent cliff looms
With its decadelong US patent for Entresto set to expire in a few months, Novartis has started to overhaul its commercial approach. The drugmaker is laying off hundreds of employees and will instead...
View ArticleJapan's RegCell raises $45.8M for Treg cell therapies, will move to US
Cell therapy biotech RegCell is hoping to bridge science from Japan with the US biotech industry to develop new cell therapies for autoimmune conditions. It announced Tuesday that it raised $45.8...
View ArticleFoodsmart names former Amwell executive Kurt Knight as CEO
Nutrition telehealth company Foodsmart tapped Kurt Knight, a former Amwell executive, to be its new CEO. The San Francisco-based company matches users with virtual dietitians and provides personalized...
View ArticleSixteen-year-old dies after receiving Sarepta’s Duchenne therapy Elevidys
A teenage boy who received Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys died from liver failure, the biotech said Tuesday morning. Sarepta told Endpoints News he was 16 years old and was...
View ArticleStoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its...
In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead drug is slated to start. The biotech
View ArticleEmpress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms
Plus, news about Pyxis Oncology, Kiromic BioPharma, TC BioPharm, EnteroBiotix, Liquidia, Compass Pathways, Vincerx Pharma and Neurizon: Empress Therapeutics undergoes layoffs: A spokesperson for the...
View ArticleHHS extends administrative leave for probationary workers after court order
Following a court order, HHS won't fire more than 2,800 probationary employees it sought to cut — but it won't let them come back to work, either. The department's update was filed Monday ...
View ArticleStem cell company bit.bio lays off quarter of staff
The British stem cell company bit.bio has reduced its workforce by 25%, impacting most of the therapeutics division, founder and board member Mark Kotter confirmed to Endpoints News. About 150...
View ArticleServier licenses Black Diamond’s RAS- and RAF-targeted drug
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer...
View ArticleFlagship's Ampersand gets Eli Lilly's support in $65M Series B
Ampersand Biomedicines, a biotech working on medicines "similar in principle" to antibody-drug conjugates, has secured $65 million in a Series B round. Eli Lilly took part in the funding round...
View Article